Stockreport

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

IceCure Medical Ltd. - Ordinary Shares  (ICCM) 
PDF IceCure working in close collaboration with FDA towards De Novo decisionCAESAREA, Israel, March 20, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", [Read more]